COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 4 for:    chiocca
Previous Study | Return to List | Next Study

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 (rQNestin)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03152318
Recruitment Status : Recruiting
First Posted : May 15, 2017
Last Update Posted : February 5, 2020
National Institutes of Health (NIH)
Advantagene, Inc. d.b.a. Candel Therapeutics
Information provided by (Responsible Party):
E. Antonio Chiocca, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : July 2022